|
23) Over the past three months, how have the price terms (for example, financing rates) offered to insurance companies as reflected across the entire spectrum of securities financing and otc derivatives transaction types changed, regardless of nonprice terms? (5)
|
|
24) Over the past three months, how has your use of nonprice terms (for example, haircuts, maximum maturity, covenants, cure periods, cross-default provisions or other documentation features) with respect to insurance companies across the entire spectrum of securities financing and otc derivatives transaction types changed, regardless of price terms? (5)
|
|
25) To the extent that the price or nonprice terms applied to insurance companies have tightened or eased over the past three months (as reflected in your responses to questions 23 and 24), what are the most important reasons for the change? (42)
|
|
26) How has the intensity of efforts by insurance companies to negotiate more favorable price and nonprice terms changed over the past three months? (5)
|
|
27) Considering the entire range of transactions facilitated by your institution for such clients, how has the use of financial leverage by insurance companies changed over the past three months? (5)
|
|
28) How has the provision of differential terms by your institution to most favored (as a function of breadth, duration, and extent of relationship) insurance companies changed over the past three months? (5)
|
